Liquid Biopsy and Cancer Interception Group (Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research), LB&CI (L5)
General information
Personnel
- Carmen Garrido Navas, Lab Associate Director
Phone: +34 958750500
Email: [email protected] - M. Jose Serrano, Principal Investigator
Phone: +34 958715500
Email: [email protected] - María José Serrano, Principal Investigator
Phone: +34 958715500
Email: [email protected]
Assertion criteria
Level: Assertion criteria provided
Summary of submissions to ClinVar
Total submissions: 166
Gene
| Gene | Submissions | Last Updated |
|---|---|---|
| ADAM19 | 5 | Feb 20, 2023 |
| ADAMTSL3 | 5 | Feb 20, 2023 |
| ADGRG6 | 3 | Feb 20, 2023 |
| AKT1 | 3 | Feb 20, 2023 |
| ALK | 1 | Feb 20, 2023 |
| ALX1 | 1 | Feb 20, 2023 |
| APC | 2 | Feb 20, 2023 |
| ATM | 6 | Aug 6, 2019 |
| BRCA1 | 5 | Aug 6, 2019 |
| BRCA2 | 4 | Aug 6, 2019 |
| C11orf65 | 4 | Aug 6, 2019 |
| CD163 | 3 | Feb 20, 2023 |
| CHEK2 | 2 | Aug 6, 2019 |
| CHRNA3 | 4 | Feb 20, 2023 |
| CHRNA5 | 3 | Feb 20, 2023 |
| CHRNB4 | 1 | Feb 20, 2023 |
| DDR2 | 3 | Feb 20, 2023 |
| EGFR | 7 | Feb 20, 2023 |
| EGR1 | 1 | Feb 20, 2023 |
| FAM13A | 2 | Feb 20, 2023 |
| FGF10 | 2 | Feb 20, 2023 |
| FLT1 | 9 | Feb 20, 2023 |
| FOXP2 | 4 | Feb 20, 2023 |
| FOXP4 | 5 | Feb 20, 2023 |
| FOXP4-AS1 | 2 | Feb 20, 2023 |
| FPR2 | 1 | Feb 20, 2023 |
| HTR4 | 3 | Feb 20, 2023 |
| IREB2 | 2 | Feb 20, 2023 |
| LOC110006318 | 2 | Feb 20, 2023 |
| LOC124849303 | 1 | Feb 20, 2023 |
| LOC126807524 | 1 | Feb 20, 2023 |
| LOC126860749 | 1 | Feb 20, 2023 |
| LOC126861112 | 1 | Feb 20, 2023 |
| LOC129996415 | 1 | Feb 20, 2023 |
| LOC129996416 | 1 | Feb 20, 2023 |
| LOC130002133 | 1 | Feb 20, 2023 |
| LOC130009460 | 1 | Feb 20, 2023 |
| MLH1 | 5 | Feb 20, 2023 |
| MSH2 | 1 | Aug 6, 2019 |
| MSH6 | 1 | Aug 6, 2019 |
| MUC5AC | 12 | Feb 20, 2023 |
| NBN | 1 | Aug 6, 2019 |
| NKX2-1 | 2 | Feb 20, 2023 |
| NLRP3 | 9 | Feb 20, 2023 |
| PALB2 | 1 | Aug 6, 2019 |
| PITX2 | 1 | Feb 20, 2023 |
| PTCH1 | 4 | Feb 20, 2023 |
| PTEN | 2 | Feb 20, 2023 |
| RAD50 | 2 | Aug 6, 2019 |
| RAD51C | 2 | Aug 6, 2019 |
| RB1 | 4 | Feb 20, 2023 |
| RIN3 | 5 | Feb 20, 2023 |
| ROS1 | 6 | Feb 20, 2023 |
| SERPINA1 | 1 | Feb 20, 2023 |
| SFTA3 | 2 | Feb 20, 2023 |
| SLC22A18 | 1 | Feb 20, 2023 |
| STK11 | 3 | Feb 20, 2023 |
| TET2 | 1 | Feb 20, 2023 |
| TET2-AS1 | 1 | Feb 20, 2023 |
| TGFB2 | 1 | Feb 20, 2023 |
| TLR4 | 5 | Feb 20, 2023 |
| TP53 | 11 | Feb 20, 2023 |
Condition
| Name | Submissions | Last Updated |
|---|---|---|
| Breast-ovarian cancer, familial, susceptibility to, 1 | 6 | Aug 6, 2019 |
| Breast-ovarian cancer, familial, susceptibility to, 2 | 7 | Aug 6, 2019 |
| Familial cancer of breast | 13 | Aug 6, 2019 |
| Lung adenocarcinoma | 101 | Feb 20, 2023 |
| Squamous cell carcinoma | 39 | Feb 20, 2023 |